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We read with interest the letter by Rohatgi et al. con-
cerning our study comparing ALPPS with PVE/PVL in a
population with mixed liver tumors [1]. Our study does not
focus only on colorectal liver metastases, as is suggested in
the letter’s title. We studied a mixed population with dif-
ferent tumor etiologies. The authors main concern is the
increased morbidity and mortality associated with ALPPS.
They also take issues with a lack of adjustment for con-
founders in comparing the groups. The authors do not agree
with our conclusion that rapid tumor removal in ALPPS
may be advantageous, citing the argument frequently raised
by the opponents of this new procedure, that failure to
reach the second stage in staged procedures for cancer is
just an unavoidable unmasking of the natural history of the
disease [2]. Ultimately, they disagree that there is an ad-
vantage to ALPPS at all.
We acknowledge—as we do in our paper—that ALPPS
is associated with a higher complication rate than con-
ventional approaches, and that this remains a concern de-
spite the lack of statistical significance. As we are stressing
in the paper, the study was not powered to detect differ-
ences in complications, but to test the hypothesis that
makes ALPPS so alluring to many surgeons across the
world: that ALPPS makes complete tumor removal feasible
in a higher number of patients than conventional ap-
proaches to staged resection and volume enhancement.
Despite the good news that ALPPS enabled complete tu-
mor removal in basically all patients in our experience, we
drew careful conclusions from the higher complication rate
(see Table 6: Recommendations for ALPPS). We analyzed
the association between ALPPS and complications in a
subsequent analysis of the International ALPPS registry
and found that age and indications other than colorectal
metastases were associated with these complications [3]. In
the early experience, which is reflected in our paper, the
operation might have been used with too much enthusiasm
as a ‘‘magic bullet’’ for a wide variety of tumors, often
primary liver tumors with cholestasis, in older patients with
extensive disease burden.
While we acknowledge the trend of a difference be-
tween a median ASA scores between the ALPPS and the
PVE/PVL group, we ultimately decided not to include
ASA score among the confounders. Due to the small cohort
size, we opted for an adequate number of confounders for
adjustment (5 confounders). We chose age (1) and gender
(2), both of which are usually included in a multivariate
analysis, additionally type of tumor (3), parenchymal
quality (4), and starting future remnant volume (5), which
are of clinical importance for the comparison of these two
procedure types. Differently from the authors of this letter,
we actually felt that the ALPPS group was rather at a
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disadvantage as compared to the PVE/PVL group as far as
the severity of tumor burden in the liver was concerned:
frequently the tumor burden motivated surgeons to use
ALPPS instead of conventional approaches. Such differ-
ences are, however, difficult to adjust for, since they are
neither captured by number nor by the size of tumors,
specifically in a mixed tumor population. To us, ‘‘type of
tumor’’ was the most important confounder that had to be
corrected when looking at outcomes.
We also observed, as did the authors of this letter, that
11 % (9/83) of patient did not undergo stage two in the
PVE/PVL group, because they developed systemic pro-
gression, while all (48/48) ALPPS patients proceeded to
stage two resection. However, we disagree with the authors
that these 11 % of patients in the PVE/PVL group would
have had no benefit from ALPPS. Because the majority of
patients with liver tumors die from the liver involvement,
the answer to the question who benefits can only be given
by survival data (and hopefully in the future: quality of life
data) for separate tumor etiologies. We recently presented a
41 % disease-free survival at 2 years after ALPPS from the
International Registry [3], a good result for ALPPS when
compared to two-stage hepatectomies for CLRM [4]. Our
point in the comparative study [1] is that the advantage of
surgical feasibility of resection in ALPPS does not translate
into an increased recurrence rate, as has been postulated by
some [2]. The argument that patients with recurrence be-
tween stages in PVE/PVL would not profit from rapid re-
section of their liver disease is treacherous since of course
conventional staged approaches with longer waiting inter-
vals will ultimately result in recurrence with prolonged
waiting time. We maintain our conclusion that only a
randomized prospective design can settle this controversy.
It is very well possible that, in the authors experience,
very few patients fail the conventional staged approach in
PVE and PVL. Like the authors, we are convinced that,
specifically in CLRM, a careful selection of patients based
on their response to chemotherapy and other predictors will
reduce the drop-out rate in these conventional staged ap-
proaches. This, however, might as well be the population
that also benefits the most from ALPPS due to a lower
complication rate. Careful selection of patients for surgery
makes a difference for both types of procedures. When we
analyzed the subgroup of patients younger than 60 years
with CLRM, we found a mortality of 5.1 % and a rate of
complications[IIIB of only 16 % [3, 5], which compares
favorably with a recently published meta-analysis for two-
stage hepatectomies [6]. The question posed by the authors
of this letter, what proportion and kind of patient would
really benefit from an ALPPS approach, will remain a
question we have to study empirically. We invite the
contributors of the International Registry (www.alpps.net)
to help us to clarify this in the future.
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